Table 1 Characteristics of the patients (n = 152) with scheduled follow-up contacts in primary health care at 12-year follow-up visit.

From: Documentation of smoking in scheduled asthma contacts in primary health care: a 12-year follow-up study

 

Patients with scheduled asthma follow-up contacts in primary health care

Number of patients

152

Female n (%)

96 (63.2)

Age (years)

59 (13)

BMI (kg/m2)

28.5 (5.9)

Smokers (ex or current) n (%)

76 (50.0)

Atopic n (%)a

51 (37.2)

Rhinitis n (%)

109 (71.7)

Uncontrolled asthma n (%)b

46 (30.3)

Daily ICS in use n (%)

125 (82.2)

Daily SABA in use n (%)

21 (13.8)

Daily LABA in use n (%)

78 (51.3)

Daily add-on drug in use n (%)

85 (55.9)

≥1 oral corticosteroid course during 12-year follow-up n (%)

50 (33.6)

Pre-BD FEV1 (%)

87 (17)

Post-BD FEV1 (%)

91 (17)

Pre-BD FEV1/FVC

0.74 (0.67–0.79)

Post-BD FEV1/FVC

0.76 (0.70–0.80)

FeNO (ppb)

11 (5–19)

Blood eosinophils (×109/l)

0.15 (0.10–0.27)

Total IgE (kU/l)

61 (23–154)

Co-existing COPD (post FEV1/FVC < 0.7 and pack-year ≥10) n (%)

19 (12.6)

ACT score

21 (19–24)

  1. If not otherwise mentioned, shown are mean (SD) or median (25th–75th percentiles). Add-on drug = long-acting β2-agonist, leukotriene receptor antagonist, theophylline, and/or tiotropium in daily use.
  2. BMI Body Mass Index, ICS inhaled corticosteroid, SABA short-acting β2-agonist, LABA long-acting β2-agonist, BD bronchodilator, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FeNO fraction of nitric oxide in exhaled air, ACT asthma control test.
  3. aAt least one positive skin prick test of common allergens.
  4. bAssessment of asthma control was performed according to the Global Initiative for Asthma (GINA) 2010 report.
Back to article page